NASDAQ:CHRS

Coherus Biosciences Stock Insider Trading

Healthcare > Biotechnology

Buy CHRS

*Your capital is at risk

$1.46

-0.0200 (-1.35%)

At Close: Jun 23, 2026

Coherus BioSciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -83.14. In total, the insiders bought 10.54M and sold 3.71M CHRS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-83.14
● Buy	10.54M shares
● Sell	3.71M shares
67% Buy Activity Negligible or No Correlation
Sell Signal Medium Confidence May 29, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -83.14. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 10, 2025 Buy	Stock Option (Right to Buy) A-Award	Lanfear Dennis M President & CEO	CEO / President	575 000 Value: $845.3K
Jan 07, 2025 Sell	Common Stock F-InKind	Mcmichael Bryan J Chief Financial Officer	C-Suite Officer	1 711 Value: $3K
Jan 07, 2025 Sell	Common Stock F-InKind	Mcmichael Bryan J Chief Financial Officer	C-Suite Officer	1 711 Value: $3K
Jan 04, 2025 Sell	Common Stock F-InKind	Lanfear Dennis M President & CEO	CEO / President	11 810 Value: $19.6K
Jan 04, 2025 Sell	Common Stock F-InKind	Reider Paul Chief Commercial Officer	Officer	2 277 Value: $4K
Jan 04, 2025 Sell	Common Stock F-InKind	Reider Paul Chief Commercial Officer	Officer	2 277 Value: $4K
Jan 04, 2025 Sell	Common Stock F-InKind	Lanfear Dennis M President & CEO	CEO / President	11 810 Value: $19.6K
Jan 03, 2025 Buy	Stock Option (Right to Buy) A-Award	Mcmichael Bryan J Chief Financial Officer	C-Suite Officer	160 000 Value: $265.6K
Jan 03, 2025 Buy	Stock Option (Right to Buy) A-Award	Reider Paul Chief Commercial Officer	Officer	160 000 Value: $265.6K
Jan 03, 2025 Buy	Stock Option (Right to Buy) A-Award	Reider Paul Chief Commercial Officer	Officer	160 000 Value: $265.6K
Jan 03, 2025 Buy	Stock Option (Right to Buy) A-Award	Mcmichael Bryan J Chief Financial Officer	C-Suite Officer	160 000 Value: $265.6K
Dec 13, 2024 Sell	Common Stock F-InKind	Reider Paul Chief Commercial Officer	Officer	2 073 Value: $3K
Dec 13, 2024 Sell	Common Stock F-InKind	Reider Paul Chief Commercial Officer	Officer	2 073 Value: $3K
Aug 07, 2024 Buy	Stock Option (Right to Buy) A-Award	Mcmichael Bryan J Chief Financial Officer	C-Suite Officer	75 000 Value: $93.0K
Aug 07, 2024 Buy	Stock Option (Right to Buy) A-Award	Mcmichael Bryan J Chief Financial Officer	C-Suite Officer	75 000 Value: $93.0K
Jul 22, 2024 Buy	Stock Option (Right to Buy) A-Award	Lanfear Dennis M President & CEO	CEO / President	196 500 Value: $473.6K
Jul 22, 2024 Buy	Stock Option (Right to Buy) A-Award	Reider Paul Chief Commercial Officer	Officer	40 000 Value: $96.4K
Jul 22, 2024 Buy	Stock Option (Right to Buy) A-Award	Reider Paul Chief Commercial Officer	Officer	40 000 Value: $96.4K
Jul 22, 2024 Buy	Stock Option (Right to Buy) A-Award	Lanfear Dennis M President & CEO	CEO / President	196 500 Value: $473.6K
Jun 04, 2024 Buy	Stock Option (Right to Buy) A-Award	Karachun Rita A Director	Director	168 000 Value: $299.0K
Jun 04, 2024 Buy	Stock Option (Right to Buy) A-Award	Erbez Georgia Director	Director	114 000 Value: $202.9K
Jun 03, 2024 Buy	Stock Option (Right to Buy) A-Award	Newton Charles W. Director	Director	112 000 Value: $197.1K
Jun 03, 2024 Buy	Stock Option (Right to Buy) A-Award	Ryan Michael Lee Director	Director	112 000 Value: $197.1K
Jun 03, 2024 Buy	Stock Option (Right to Buy) A-Award	Wahlstrom Mats Director	Director	112 000 Value: $197.1K
May 31, 2024 Buy	Common Stock J-Other	Karachun Rita A Insider	Other	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT COHERUS BIOSCIENCES

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ...

Read Full Profile Here